FindTrial
Sign In

Significance of Combining 68Ga-FAPI PET/CT, Clinical and Pathological Features in Predicting Pathological Response to Neoadjuvant Immunotherapy Combined with Chemotherapy for Locally Advanced Gastric Cancer

Significance of Combining 68Ga-FAPI PET/CT, Clinical and Pathological Features in Predicting Pathological Response to Neoadjuvant Immunotherapy Combined with Chemotherapy for Locally Advanced Gastric Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128675
Enrollment
Unknown
Registered
2026-07-23
Start date
2026-07-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with locally advanced gastric cancer receiving neoadjuvant chemoimmunotherapy.

Interventions

FAPI-PET/CT group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 75 years old; 2.Pathologically confirmed with gastric adenocarcinoma or Siewert type II/III esophagogastric junction adenocarcinoma; 3.Underwent baseline 68Ga-FAPI PET/CT examination prior to treatment initiation; 4.Received neoadjuvant chemotherapy combined with immunotherapy for at least two cycles; 5.Underwent radical resection after completion of neoadjuvant therapy; 6.Possessed complete CT imaging data and clinical medical records;

Exclusion criteria

Exclusion criteria: 1.Received any other anti-tumor therapies before baseline PET/CT scan; 2.Pathological type was adenosquamous carcinoma;

Design outcomes

Primary

MeasureTime frame
Pathological response;—

Countries

China

Contacts

Public ContactGou Hongfeng

West China Hospital of Sichuan University

gouhongfeng1977@wchscu.cn+86 755 85423610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026